Ioxilan

Ioxilan Overview

Ioxilan (chemically designated as 5-[N-(2,3-dihydroxypropyl)acetamido]-

N1-(2,3-dihydroxypropyl)-N3-(2-hydroxyethyl)-2,4,6-triiodoisophthalamide; chemical formula C18H24I3N3O8) is a non-ionic, low-osmolar monomeric tri-iodinated benzamide derivative. Chemically, it belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives within the benzoic acids and derivatives sub-class of benzenoids. Structurally, it consists of a benzene ring substituted with three iodine atoms at positions 2, 4, and 6, and hydrophilic aliphatic hydroxyalkylamide side chains designed to lower chemotoxicity and osmolality.

In diagnostic radiology, cardiology, and nephrology, Ioxilan functions as a water-soluble, nephrotropic low-osmolar X-ray contrast medium (ATC code V08AB12 for water-soluble, nephrotropic, low-osmolar X-ray contrast media). Formulated as sterile intravascular injection solutions (marketed under the trade name Oxilan in concentrations of 300 mgI/mL and 350 mgI/mL), it is indicated for diagnostic radiologic visualization during cerebral arteriography, coronary arteriography, left ventriculography, visceral angiography, aortography, peripheral arteriography, excretory urography, and contrast-enhanced computed tomography (CECT) of the head and body. First approved by the US FDA in December 1995, it offered improved vascular tolerability compared to older high-osmolar ionic agents before its commercial distribution was voluntarily discontinued.

What Is Ioxilan and How Does It Work?

Ioxilan acts primarily through X-ray beam attenuation mediated by high-density iodine atoms, allowing radiopaque opacification of blood vessels, organ parenchyma, and renal excretion pathways.

Its primary chemical, physiological, and diagnostic mechanisms include:

• Radiopaque X-Ray Attenuation: The three organically bound iodine atoms per molecule absorb X-ray photons via the photoelectric effect due to iodine’s high atomic number (Z = 53) and K-shell binding energy (33.2 keV). This radiopaque density blocks X-ray penetration, producing visual contrast between vascular lumens or tissues and surrounding anatomical structures until hemodilution occurs.
• Low Osmolality Solution Dynamics: As a non-ionic monomer, Ioxilan does not dissociate into charged ions in solution. This non-ionic structure significantly lowers solution osmolality relative to ionic contrast agents, reducing osmotic fluid shifts from tissue spaces into the vascular bed and minimizing pain, vasodilation, and endothelial damage upon intravascular injection.
• Rapid Glomerular Filtration: Following intravascular injection, Ioxilan is rapidly distributed throughout the extracellular fluid and filtered unchanged by renal glomeruli without significant tubular reabsorption or secretion, concentrating radiopaque dye within the urinary tract.

Is Ioxilan FDA Approved?

Ioxilan was approved by the US FDA in December 1995 under the brand name Oxilan. The manufacturer later voluntarily discontinued its commercial distribution. Its current approval status is FDA Approved (December 1995); Discontinued (October 2017).

What Was Ioxilan Used For?

• Intra-arterial diagnostic procedures including cerebral arteriography, coronary arteriography, left ventriculography, visceral angiography, aortography, and peripheral arteriography.
• Intravenous excretory urography to evaluate renal structure, collecting systems, ureters, and bladder.
• Contrast-enhanced computed tomography (CECT) imaging of the head and body to detect lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, and retroperitoneum.

Before Taking Ioxilan: Contraindications & Precautions

Do not administer Ioxilan intrathecally, as accidental subarachnoid injection of non-approved contrast media can cause severe neurological toxicity, convulsions, and death. Avoid intravascular administration in patients with a history of severe hypersensitivity to Ioxilan or iodine-containing contrast agents. Exercise extreme caution in patients with severe renal impairment, combined renal and hepatic disease, diabetes mellitus, multiple myeloma, pheochromocytoma, or severe hyperthyroidism.

Who Should Not Take Ioxilan?

• Individuals with known severe hypersensitivity or immediate anaphylactoid reaction to Ioxilan, iodine, or formulation excipients.
• Patients undergoing intrathecal (spinal) procedures (not approved for intrathecal use).

Ioxilan, Pregnancy & Reproductive Safety

Ioxilan crosses the human placenta following intravascular administration. Preclinical animal studies revealed no direct teratogenic effects, but high-osmolar or low-osmolar radiopaque contrast media crossing the placenta can potentially affect fetal thyroid function. Diagnostic radiologic procedures involving contrast should be performed during pregnancy only when essential. Trace amounts pass into breast milk, but gastrointestinal absorption by the infant is minimal; mothers may pause breastfeeding for 24 hours post-procedure if desired.

Tell Your Doctor Before Taking Ioxilan

Inform your radiologist or physician if you have a history of severe asthma, food or drug allergies, chronic kidney disease, diabetes mellitus, congestive heart failure, multiple myeloma, or thyroid disease.

Ioxilan Dosage & Administration

Formulated as sterile intravascular injection solutions containing 300 mgI/mL (62.3% ioxilan) or 350 mgI/mL (72.7% ioxilan).

Standard Ioxilan Dosing

• Cerebral Arteriography (300 mgI/mL): Administered as 8 mL to 12 mL per injection into carotid or vertebral arteries, repeated as necessary up to a maximum total volume.
• Coronary Arteriography & Left Ventriculography (350 mgI/mL): Administered as 2 mL to 10 mL per coronary artery injection, or 30 mL to 50 mL for left ventriculography.
• CECT Head/Body & Excretory Urography (300 or 350 mgI/mL): Administered as 50 mL to 150 mL intravenously depending on patient weight and imaging requirements.

How Ioxilan Was Administered

• Administered intravascularly via rapid bolus or power injector by trained radiology personnel.
• Ensure adequate patient hydration before and after contrast administration to mitigate contrast-induced acute kidney injury.

Ioxilan Clinical Efficacy & Safety Profile

Clinical trials demonstrated that Oxilan provided excellent tissue opacification and vascular visualization comparable to other non-ionic low-osmolar agents (such as iohexol and iopamidol). Because of its non-ionic structure and lower osmolality, Ioxilan generated significantly fewer sensations of heat, injection-site pain, hemodynamic changes, and nausea compared to older high-osmolar ionic agents.

Ioxilan Side Effects & Safety Profile

Common reactions were mild and transient, including feeling of warmth, flushing, mild nausea, headache, dizziness, and taste alterations. Serious adverse risks included severe anaphylactoid shock, contrast-induced acute kidney injury (CI-AKI), cardiac arrhythmias, bronchospasm, and seizures. Holds no FDA Black Box Warning.

Common Ioxilan Side Effects

• Vascular / Systemic: Sensation of warmth or mild flushing, transient nausea, dizziness, headache, and metallic taste.
• Local: Mild discomfort or warmth at the injection site.

Serious Ioxilan Adverse Events

• Severe Hypersensitivity / Anaphylaxis: Immediate urticaria, laryngeal edema, severe bronchospasm, profound hypotension, and fatal anaphylactoid shock.
• Contrast-Induced Acute Kidney Injury (CI-AKI): Acute renal tubular necrosis, oliguria, and transient elevation of serum creatinine, particularly in dehydrated or diabetic patients.
• Cardiovascular Toxicity: Transient ECG changes, arrhythmias, angina, or hypotension during coronary angiography.

Managing Ioxilan Side Effects

Maintain emergency resuscitation equipment, oxygen, epinephrine, and intravenous fluids in the imaging suite. Pre-procedure hydration reduces nephrotoxicity risks.

Ioxilan Drug Interactions & What to Avoid

Co-administration with nephrotoxic or biguanide medications required specific clinical precautions.

Ioxilan Drug-Drug Interactions

• Metformin: Intravascular contrast-induced renal impairment can lead to metformin accumulation, risking fatal lactic acidosis; metformin should be temporarily withheld at the time of the procedure in patients with reduced eGFR.
• Nephrotoxic Drugs (e.g., Aminoglycosides, NSAIDs, Amphotericin B): Concurrent use increases the risk of contrast-induced acute kidney injury.
• Radioactive Iodine (I-131): Administration saturates thyroid iodine uptake capacity, interfering with diagnostic thyroid scans or radioiodine therapy for 2 to 6 weeks.

Ioxilan, Food & Alcohol

Maintain robust fluid intake prior to contrast procedures to ensure adequate hydration. Avoid alcohol intake prior to imaging to prevent pre-existing dehydration.

Ioxilan: Missed Dose, Overdose & Storage

Administered as a single diagnostic procedure dose. Overdose causes fluid overload and renal strain. Store at controlled room temperature (15°C–25°C).

Missed Dose of Ioxilan

Not applicable; administered as a single, scheduled diagnostic procedure by healthcare professionals.

Ioxilan Overdose & Emergency

Intravascular overdose leads to hypervolemia, severe hemodynamic instability, pulmonary edema, renal failure, and electrolyte imbalances. Management involves supportive cardiovascular care, fluid management, and hemodialysis if severe renal impairment occurs.

How to Store Ioxilan

Store sterile injection solutions at controlled room temperature between 15°C and 25°C (59°F to 77°F). Protect from light and freezing. Discard unused portions in single-dose containers immediately. Keep strictly out of reach of children.

Ioxilan Patient Management & Monitoring

Requires baseline renal function assessment and post-procedure hydration tracking.

Tests Before Starting Ioxilan

Baseline serum creatinine, estimated glomerular filtration rate (eGFR), hydration status evaluation, and screening for prior contrast allergies.

Monitoring During Ioxilan Treatment

Continuous vital sign monitoring (blood pressure, pulse, pulse oximetry) during and for at least 30 minutes post-injection to detect immediate hypersensitivity reactions.

Ioxilan Do’s and Don’ts

• Do ensure adequate hydration before and after receiving intravenous contrast.
• Do inform the radiologist immediately if you experience shortness of breath, throat tightness, or severe itching.
• Do not undergo contrast procedures without informing medical staff of pre-existing kidney disease or diabetes.
• Do not resume metformin therapy after contrast exposure until renal function is confirmed stable.

Frequently Asked Questions

References

• DrugBank Database – Ioxilan Clinical Profile (DB09135)
• Classyfire Database – Acylaminobenzoic Acid / Benzenoids Taxonomy Profile
• US FDA Prescribing Information – Oxilan (Ioxilan Injection) Records

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.